Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Incidence of muscle relaxant use in relation to diagnosis of Parkinson's disease.

Paakinaho A, Karttunen N, Koponen M, Taipale H, Tolppanen AM, Hartikainen S, Tiihonen M.

Int J Clin Pharm. 2020 Mar 6. doi: 10.1007/s11096-020-01002-7. [Epub ahead of print]

PMID:
32144610
2.

Psychotropic Drug-Associated Pneumonia in Older Adults.

Rajamaki B, Hartikainen S, Tolppanen AM.

Drugs Aging. 2020 Apr;37(4):241-261. doi: 10.1007/s40266-020-00754-1. Review.

3.

Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.

Lampela P, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Taipale H.

J Alzheimers Dis. 2020;73(3):1243-1251. doi: 10.3233/JAD-190850.

PMID:
31929157
4.

The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease.

Tapiainen V, Lavikainen P, Koponen M, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

J Am Geriatr Soc. 2020 Mar;68(3):595-602. doi: 10.1111/jgs.16275. Epub 2020 Jan 7.

PMID:
31912482
5.

Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer's Disease.

Lintula E, Tiihonen M, Taipale H, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Hamina A.

Drugs Aging. 2020 Mar;37(3):193-203. doi: 10.1007/s40266-019-00734-0.

6.

Pelvic organ prolapse surgery and quality of life-a nationwide cohort study.

Mattsson NK, Karjalainen PK, Tolppanen AM, Heikkinen AM, Sintonen H, Härkki P, Nieminen K, Jalkanen J.

Am J Obstet Gynecol. 2019 Dec 11. pii: S0002-9378(19)32723-1. doi: 10.1016/j.ajog.2019.11.1285. [Epub ahead of print]

PMID:
31836546
7.

Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease.

Vu M, Koponen M, Taipale H, Tanskanen A, Tiihonen J, Kettunen R, Hartikainen S, Tolppanen AM.

Int J Cardiol. 2020 Feb 1;300:221-225. doi: 10.1016/j.ijcard.2019.09.036. Epub 2019 Oct 30.

PMID:
31810814
8.

Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study.

Sluggett JK, Koponen M, Bell JS, Taipale H, Tanskanen A, Tiihonen J, Uusitupa M, Tolppanen AM, Hartikainen S.

J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii: dgz234. doi: 10.1210/clinem/dgz234.

PMID:
31778170
9.

Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation.

Heiskanen J, Hartikainen J, Martikainen J, Miettinen H, Hippeläinen M, Roine RP, Tolppanen AM.

Eur J Clin Pharmacol. 2020 Jan;76(1):81-88. doi: 10.1007/s00228-019-02735-9. Epub 2019 Oct 11.

PMID:
31605162
10.

Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.

Koponen M, Lavikainen P, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

J Am Med Dir Assoc. 2019 Dec;20(12):1488-1494.e3. doi: 10.1016/j.jamda.2019.07.009. Epub 2019 Aug 26.

11.

Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease.

Kalamägi J, Lavikainen P, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

Ann Med. 2019 Aug - Sep;51(5-6):294-305. doi: 10.1080/07853890.2019.1642507. Epub 2019 Aug 12.

PMID:
31322423
12.

The relationship of defecation symptoms and posterior vaginal wall prolapse in women undergoing pelvic organ prolapse surgery.

Karjalainen PK, Mattsson NK, Nieminen K, Tolppanen AM, Jalkanen JT.

Am J Obstet Gynecol. 2019 Nov;221(5):480.e1-480.e10. doi: 10.1016/j.ajog.2019.05.027. Epub 2019 May 22.

PMID:
31128111
13.

Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer's Disease.

Hamina A, Taipale H, Karttunen N, Tanskanen A, Tiihonen J, Tolppanen AM, Hartikainen S.

J Alzheimers Dis. 2019;69(3):807-816. doi: 10.3233/JAD-181295.

PMID:
31127778
14.

Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy?

Cui LL, Golubczyk D, Tolppanen AM, Boltze J, Jolkkonen J.

Ann Neurol. 2019 Jul;86(1):5-16. doi: 10.1002/ana.25493. Epub 2019 May 8. No abstract available.

PMID:
31020699
15.

Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer's disease-nested case-control study.

Taipale H, Rysä J, Hukkanen J, Koponen M, Tanskanen A, Tiihonen J, Kröger H, Hartikainen S, Tolppanen AM.

Osteoporos Int. 2019 Jul;30(7):1481-1489. doi: 10.1007/s00198-019-04957-0. Epub 2019 Apr 16.

16.

Incidence of head injury and traumatic brain injury among people with Alzheimer's disease.

Ilmaniemi S, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

J Epidemiol Community Health. 2019 May;73(5):451-454. doi: 10.1136/jech-2018-211960. Epub 2019 Feb 19.

PMID:
30782855
17.

Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer's Disease-Matched Cohort Study.

Taipale H, Lampela P, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

J Alzheimers Dis. 2019;68(1):127-136. doi: 10.3233/JAD-180912.

18.

Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease.

Lavikainen P, Taipale H, Tanskanen A, Koponen M, Tiihonen J, Hartikainen S, Tolppanen AM.

J Am Med Dir Assoc. 2019 Jun;20(6):751-758. doi: 10.1016/j.jamda.2018.11.012. Epub 2019 Jan 7.

19.

Methods of surgery for pelvic organ prolapse in a nationwide cohort (FINPOP 2015).

Mattsson NK, Karjalainen P, Tolppanen AM, Heikkinen AM, Jalkanen J, Härkki P, Nieminen K.

Acta Obstet Gynecol Scand. 2019 Apr;98(4):451-459. doi: 10.1111/aogs.13520. Epub 2019 Feb 3.

PMID:
30578530
20.

Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease.

Kettunen R, Taipale H, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Koponen M.

Eur J Clin Pharmacol. 2019 Mar;75(3):417-425. doi: 10.1007/s00228-018-2591-5. Epub 2018 Nov 9.

PMID:
30413841
21.

Antiepileptic Drug Use and the Risk of Stroke Among Community-Dwelling People With Alzheimer Disease: A Matched Cohort Study.

Sarycheva T, Lavikainen P, Taipale H, Tiihonen J, Tanskanen A, Hartikainen S, Tolppanen AM.

J Am Heart Assoc. 2018 Sep 18;7(18):e009742. doi: 10.1161/JAHA.118.009742.

22.

Concomitant use of benzodiazepines and opioids in community-dwelling older people with or without Alzheimer's disease-A nationwide register-based study in Finland.

Karttunen N, Taipale H, Hamina A, Tanskanen A, Tiihonen J, Tolppanen AM, Hartikainen S.

Int J Geriatr Psychiatry. 2019 Feb;34(2):280-288. doi: 10.1002/gps.5018. Epub 2018 Nov 27.

PMID:
30370943
23.

Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study.

Taipale H, Hamina A, Karttunen N, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

Pain. 2019 Feb;160(2):417-423. doi: 10.1097/j.pain.0000000000001412.

PMID:
30325873
24.

Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005-2012: A Nationwide Exposure-Matched Cohort Study.

Tolppanen AM, Tiihonen M, Taipale H, Koponen M, Tanskanen A, Lavikainen P, Tiihonen J, Hartikainen S.

Drugs Aging. 2018 Nov;35(11):985-992. doi: 10.1007/s40266-018-0591-x.

25.

Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease.

Sarycheva T, Taipale H, Lavikainen P, Tiihonen J, Tanskanen A, Hartikainen S, Tolppanen AM.

J Alzheimers Dis. 2018;66(1):387-395. doi: 10.3233/JAD-180594.

26.

Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease.

Orsel K, Taipale H, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Gardarsdottir H, Hartikainen S.

Eur Neuropsychopharmacol. 2018 Nov;28(11):1260-1269. doi: 10.1016/j.euroneuro.2018.04.005. Epub 2018 Aug 25.

PMID:
30153953
27.

Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study.

Orsel K, Taipale H, Raatikainen S, Lampela P, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Gardarsdottir H, Hartikainen S.

J Clin Psychopharmacol. 2018 Oct;38(5):494-497. doi: 10.1097/JCP.0000000000000928.

PMID:
30102630
28.

Reply to: Use of Antiepileptic Drugs and Dementia Risk-an Analysis of Finnish Health Register and German Health Insurance Data.

Taipale H, Gomm W, Broich K, Maier W, Tolppanen AM, Hartikainen S, Haenisch B.

J Am Geriatr Soc. 2018 Sep;66(9):1853-1854. doi: 10.1111/jgs.15512. Epub 2018 Aug 9. No abstract available.

PMID:
30094822
29.

Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer's Disease: Retrospective Register-Based Cohort Study.

Järvinen H, Taipale H, Koponen M, Tanskanen A, Tiihonen J, Tolppanen AM, Hartikainen S.

J Alzheimers Dis. 2018;64(2):437-445. doi: 10.3233/JAD-180125.

PMID:
29914029
30.

Editorial: let's take a break from studying the PPI-fracture association-Authors' reply.

Torvinen-Kiiskinen S, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Taipale H.

Aliment Pharmacol Ther. 2018 Jun;47(11):1544-1545. doi: 10.1111/apt.14666. No abstract available.

31.

The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case-control study.

Tapiainen V, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

Acta Psychiatr Scand. 2018 Aug;138(2):91-100. doi: 10.1111/acps.12909. Epub 2018 May 31.

PMID:
29851063
32.

Use of Antiepileptic Drugs and Dementia Risk-an Analysis of Finnish Health Register and German Health Insurance Data.

Taipale H, Gomm W, Broich K, Maier W, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Haenisch B.

J Am Geriatr Soc. 2018 Jul;66(6):1123-1129. doi: 10.1111/jgs.15358. Epub 2018 Mar 22.

PMID:
29566430
33.

Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease.

Hamina A, Lavikainen P, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S, Taipale H.

Int Psychogeriatr. 2018 Jul;30(7):947-956. doi: 10.1017/S1041610217002897. Epub 2018 Mar 21.

PMID:
29559009
34.

Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.

Torvinen-Kiiskinen S, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Taipale H.

Aliment Pharmacol Ther. 2018 Apr;47(8):1135-1142. doi: 10.1111/apt.14589. Epub 2018 Mar 6.

35.

Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study.

Saarelainen L, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Taipale H.

Int J Geriatr Psychiatry. 2018 Apr;33(4):583-590. doi: 10.1002/gps.4821. Epub 2017 Nov 15.

PMID:
29143367
36.

Does routinely collected patient-reported outcome data represent the actual case-mix of elective coronary revascularization patients?

Oinasmaa S, Heiskanen J, Hartikainen J, Hippeläinen M, Miettinen H, Martikainen J, Roine RP, Tolppanen AM.

Eur Heart J Qual Care Clin Outcomes. 2018 Apr 1;4(2):113-119. doi: 10.1093/ehjqcco/qcx038.

PMID:
29045602
37.

Targeted identification of adverse events in coronary artery disease patients based on patient-reported outcomes.

Heiskanen J, Tolppanen AM, Martikainen J, Hartikainen J, Miettinen H, Hippeläinen M, Roine RP.

J Comp Eff Res. 2017 Oct;6(7):583-589. doi: 10.2217/cer-2016-0091. Epub 2017 Oct 17.

PMID:
29039972
38.

Is Alzheimer's Disease Associated with Previous Opioid Use?

Taipale H, Hamina A, Lampela P, Tanskanen A, Tiihonen J, Karttunen N, Tolppanen AM, Hartikainen S.

Pain Med. 2018 Nov 1;19(11):2115-2121. doi: 10.1093/pm/pnx210.

PMID:
29025166
39.

Drug exposure in register-based research-An expert-opinion based evaluation of methods.

Tanskanen A, Taipale H, Koponen M, Tolppanen AM, Hartikainen S, Ahonen R, Tiihonen J.

PLoS One. 2017 Sep 8;12(9):e0184070. doi: 10.1371/journal.pone.0184070. eCollection 2017.

40.

Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study.

Taipale H, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S, Tolppanen AM.

Alzheimers Res Ther. 2017 Aug 1;9(1):59. doi: 10.1186/s13195-017-0285-3.

41.

No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease.

Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S.

Am J Gastroenterol. 2017 Dec;112(12):1802-1808. doi: 10.1038/ajg.2017.196. Epub 2017 Jul 11.

PMID:
28695906
42.

Head or brain injuries and Alzheimer's disease: A nested case-control register study.

Tolppanen AM, Taipale H, Hartikainen S.

Alzheimers Dement. 2017 Dec;13(12):1371-1379. doi: 10.1016/j.jalz.2017.04.010. Epub 2017 Jun 7.

PMID:
28599121
43.

Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.

Juntunen H, Taipale H, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S, Tiihonen M.

Eur J Clin Pharmacol. 2017 Sep;73(9):1149-1158. doi: 10.1007/s00228-017-2273-8. Epub 2017 Jun 2.

PMID:
28577224
44.

Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease.

Tolppanen AM, Taipale H, Koponen M, Tanskanen A, Lavikainen P, Paananen J, Tiihonen J, Hartikainen S.

Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):875-889. doi: 10.1002/pds.4232. Epub 2017 May 29.

PMID:
28556303
45.

Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer's Disease.

Hyttinen V, Taipale H, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Valtonen H.

Ann Pharmacother. 2017 Sep;51(9):725-734. doi: 10.1177/1060028017708394. Epub 2017 May 9.

PMID:
28486815
46.

Validation of the short forms of the Pelvic Floor Distress Inventory (PFDI-20), Pelvic Floor Impact Questionnaire (PFIQ-7), and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in Finnish.

Mattsson NK, Nieminen K, Heikkinen AM, Jalkanen J, Koivurova S, Eloranta ML, Suvitie P, Tolppanen AM.

Health Qual Life Outcomes. 2017 May 2;15(1):88. doi: 10.1186/s12955-017-0648-2.

47.

Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease.

Taipale H, Tolppanen AM, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S.

CMAJ. 2017 Apr 10;189(14):E519-E529. doi: 10.1503/cmaj.160126.

48.

Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study.

Tapiainen V, Hartikainen S, Taipale H, Tiihonen J, Tolppanen AM.

Eur Psychiatry. 2017 Jun;43:92-98. doi: 10.1016/j.eurpsy.2017.02.486. Epub 2017 Mar 9.

PMID:
28388490
49.

Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's disease in 2005-2011.

Tolppanen AM, Voutilainen A, Taipale H, Tanskanen A, Lavikainen P, Koponen M, Tiihonen J, Hartikainen S.

PLoS One. 2017 Mar 9;12(3):e0173450. doi: 10.1371/journal.pone.0173450. eCollection 2017.

50.

Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study.

Imtiaz B, Taipale H, Tanskanen A, Tiihonen M, Kivipelto M, Heikkinen AM, Tiihonen J, Soininen H, Hartikainen S, Tolppanen AM.

Maturitas. 2017 Apr;98:7-13. doi: 10.1016/j.maturitas.2017.01.002. Epub 2017 Jan 9.

PMID:
28274328

Supplemental Content

Loading ...
Support Center